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http://www.biomedcentral.com/1471-5945/12/19RESEARCH ARTICLE Open AccessWhat determines patient preferences for treating
low risk basal cell carcinoma when comparing
surgery vs imiquimod? A discrete choice
experiment survey from the SINS trial
Michela Tinelli1, Mara Ozolins2*, Fiona Bath-Hextall2 and Hywel C Williams2Abstract
Background: The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) is a randomised
controlled trial evaluating long term success of excisional surgery vs. imiquimod 5% cream for low risk nodular and
superficial basal cell carcinoma (BCC). The trial included a discrete choice experiment questionnaire to explore
patient preferences of a cream versus surgery for the treatment of their skin cancer.
Methods: The self-completed questionnaire was administered at baseline to 183 participants, measuring patients’
strength of preferences when choosing either alternative ‘surgery’ or ‘imiquimod cream’ instead of a fixed ‘current
situation’ option (of surgical excision as standard practice in UK). The treatments were described according to: cost,
chance of complete clearance, side effects and appearance. Participants had to choose between various scenarios.
Analysis was performed using a mixed logit model, which took into account the impact of previous BCC treatment
and sample preference variability.
Results: The analysis showed that respondents preferred ‘imiquimod cream’ to their ‘current situation’ or ‘surgery’,
regardless of previous experience of BCC symptoms and treatment. Respondents were more likely to be worried
about their cosmetic outcomes and side effects they might experience over and above their chance of clearance
and cost. Those with no experience of surgery (compared with experience) valued more the choice of ‘imiquimod
cream’ (£1013 vs £781). All treatment characteristics were significant determinants of treatment choice, and there
was significant variability in the population preferences for all of them.
Conclusions: Patients with BCC valued more ‘imiquimod cream’ than alternative ‘surgery’ options, and all treatment
characteristics were important for their choice of care. Understanding how people with a BCC value alternative
interventions may better inform the development of health care interventions.
Keywords: Patient preferences, Discrete choice, Willingness to pay, Nodular and superficial basal cell carcinoma,
Surgery, Imiquimod creamBackground
To make an informed choice when choosing between
surgery and imiquimod cream treatments for low risk
basal cell carcinomas (BCCs) such as superficial BCC or
small nodular BCC not located on the central face (as
specified by the British Association of Dermatology* Correspondence: Mara.Ozolins@Nottingham.ac.uk
2Centre of Evidence Based Dermatology, University of Nottingham, A103,
King’s Meadow Campus, Lenton Lane, Nottingham NG7 2NR, UK
Full list of author information is available at the end of the article
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reproduction in any medium, provided the orBCC treatment guidelines [1]), patients need to balance
trade-offs between different aspects (e.g. risk of scarring,
clearance, and out-of-pocket costs) attached to these al-
ternative treatments (Weston and Fitzgerald [2]; Essers
et al. [3]). Our aim was to investigate patient preferences
for ‘surgery’ or ‘imiquimod cream’ for the treatment of
BCC using a discrete choice experiment (DCE; Ryan
et al. [4]) approach in a sample of patients participating
in a randomised controlled trial of surgery vs. imiquimod
for low risk nodular and superficial BCC (Ozolins et al.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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technique as it has been previously used in health care to
evaluate different cancer screening strategies (Words-
worth et al. [6]; Marshall et al. [7]; Kruijshaar et al. [8];
van Dam et al. [9]; Hol et al. [10]); and willingness to pay
(WTP) for methyl aminolevulinate photodynamic ther-
apy vs surgery in BCC (Weston and Fitzgerald [2]) and
for Mohs micrographic surgery vs surgery (Essers et al.
[3]). Patient experience with previous treatment has been
shown to influence the utility (benefit) patients derive
from health care interventions (Salkeld et al. [11]; Ryan
and Ubach [12]; Cheraghi-Sohi et al. [13]). We are also
aware that information from such experiments can help
health professionals to understand individual preferences
for treatment, and, indeed, inform policy (Eberth et al.
[14]; De Bekker-Grob et al. [15]). To our knowledge
there is no evidence of research investigating: i) how
patients with a BCC value alternative treatments on offer
ii) the extent of preference variability or heterogeneity in
the sample and iii) bearing in mind that BCCs are often
asymptomatic and multiple, whether patients with ex-
perience of tumour symptoms and previous treatments
may have better informed preferences. This study investi-
gates how patients with a low risk BCC participating in a
randomized controlled trial of excisional surgery versus
topical imiquimod value the choice between the two
treatment modalities.
Methods
The Discrete Choice Experiment (DCE) questionnaire
The Discrete Choice Experiment (DCE) technique is an
attribute based approach that quantifies strength of
patients’ preferences for the health care services or inter-
ventions. Respondents choose between alternative hypo-
thetical interventions described in terms of their
characteristics and associated levels. Results from the re-
gression model identify which attributes, such as chance
of clearance, side effects or convenience, are significant in
the decision to choose, and their relative importance
across treatments (i.e. magnitude of the attributes). Money
as an attribute can also be used to estimate trade-off or
Willingness To Pay (WTP, a monetary measure of benefit)
for changes in attribute levels (e.g. WTP for improving by
1% their chance of clearance). The DCE technique, and its
application to health care, is extensively discussed else-
where (Ryan et al. [4]; de Bekker-Grob et al. [15]).
In this experiment, a list of attributes, their levels,
and status quo alternative (see below) were derived
from a previous DCE exercise applied to BCC (Weston
et al. [2]), and from systematic discussion with the re-
search team plus advice provided by a panel of
experts. They were chosen to be general aspects of
treatment that best described the alternative interven-
tions on offer within the SINS trial i.e. ‘surgery’ vs.‘imiquimod cream’ (Table 1). The “cost to you” attri-
bute was added to find out how much patients valued
the treatment. How the treatments and attributes were
presented to the participants can be seen in the ques-
tionnaire (see Additional file 1).
A DCE labelled (‘surgery’ vs. ‘imiquimod cream’) experi-
ment was created from design catalogues [16] using a
fold-over approach (Louviere et al. [17]; Rose and Bliemer
[18]), as a commonly used technique to inform experi-
mental design creation (de Bekker-Grob et al. [15]).
Employing such a design minimised the number of
choices for each respondent, from 135 (51*33) to 16
choices. To the 16-choice design, a third status quo alter-
native was added, representing surgical excision as current
(standard) practice in UK hospitals (i.e. ‘current situation’).
It defined an average surgical excision in a hospital setting
with a 4 mm clear excision margin, use of a local anaes-
thetic injection, closure with sutures and removal of
sutures on a separate visit. The ‘current situation’ was
characterised by the following fixed levels: 96% chance of
complete clearance; mild pain (that does not disturb
sleep); a noticeable (but easy to cover) scar after treat-
ment; and £0 cost to the patient (the procedure was
undertaken free at the point of care in the UK National
Health Service). An example of a choice is reported in
Figure 1.
Participants, sample size, setting and data collection
Our study sample included men and women of any age
with low risk [1] nodular or superficial BCC participat-
ing in the SINS (Surgery vs Imiquimod in Nodular and
Superficial basal cell carcinoma) study [5]. The SINS
study is a randomized controlled trial to compare exci-
sion ‘surgery’ and ‘imiquimod cream’ for nodular and
superficial basal cell carcinoma presenting in low risk
areas. The study (ISRCTN48755084) received full ethical
and hospital approval, and is conducted according to the
declaration of Helsinki; all participants gave informed
written consent.
Since size, type of experimental design, and the num-
ber of independent variables were unknown in advance,
a minimum estimate of 50–100 responses per subgroup
of interest was stipulated. The questionnaire was distribu-
ted to 183 of 501 consecutive patients participating in the
trial (18th to 200th), during their baseline visit (August
2003-January 2005). A minimum target response of 170
(response rate of 85%), allowing for comparison be-
tween two subgroups with experience and with no
experience of BCC and treatment, was felt appropriate
compared with similar studies (Pearmain et al. [19]).
Analysis
Response rates, patient characteristics, and questionnaire
completion: Descriptive statistics were presented as
SURGERY CREAM CURRENT 
SITUATION
Chance of complete 
clearance (%)
96 90 96
Side Effects Moderate pain Severe irritation, 
burning, redness or 
ulceration
Mild pain
Appearance after 
treatment
Slightly raised 
permanent scar
Skin as normal Noticeable scar
Cost to you 150 300 0
Which situation would 
you prefer?
(Tick one box only)
SURGERY CREAM CURRENT 
SITUATION
Figure 1 Example of Choice Set.
Table 1 Summary of coding for discrete choice experiment attributes and their levels
Attributes Attribute levels Variable names
Surgery Imiquimod cream Current situation
1) Cost [cost to you] £0 £0 £0 COST
£150 £150
£300 £300
£500 £500
£750 £750
2) Chance [Chance of
complete clearance]
94% 50% 96% CHANCE
96% 70%
98% 90%
3) Side effects MILD MILD MILD MILD SIDE EFFECTS
(mild pain that does
not disturb sleep)
(Mild irritation,
burning or redness)
(mild pain that does
not disturb sleep)
MODERATE MODERATE MODERATE SIDE EFFECTS
(pain that sometimes
might disturb sleep)
(Moderate irritation, burning,
redness or weeping)
SEVERE SEVERE (compared with severe)
(pain that disturbs sleep) (Severe irritation, burning,
redness or ulceration)
4) Appearance NORMAL NORMAL MODERATE CHANGE NORMAL APPEARANCE
(Barely visible scar) (Not discoloured skin) (noticeable scar)
MODERATE CHANGE MODERATE CHANGE MODERATE CHANGE IN APPEARANCE
(Noticeable scar) (Slight lightening skin)
SEVERE CHANGE SEVERE CHANGE (compared with severe change)
(Slightly raised scar) (Discoloured skin)
ALTERNATIVES SURGERY IMIQUIMOD CREAM CURRENT SITUATION SURGERY
(fixed surgery option from
their experience alternative
to an hypothetical ‘surgery’)
CREAM
(compared with
current situation)
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dian and inter-quartile range (continuous variables).
Differences in patient characteristics between sub-
groups with experience and with no experience were
reported and tested using the non parametric Mann–
Whitney test and Chi square tests (where appropriate).
SPSS software version 16 [20] was used to analyse the
data.
Patient preferences: DCE modelling, its theoretical val-
idity and subgroup analysis. Patient preference data were
analysed using the mixed logit model (MLM, largely ap-
plied to multiple choice health care data, de Bekker-Grob
et al. [15]). The Biogeme package [21] was used to support
this analysis. Theoretical validity of responses was checked
by testing the direction and significance of the model attri-
butes. A priori we expected respondents to prefer: a
decreased cost (a negative sign for ‘COST’); an increased
chance of complete clearance (positive sign for
‘CHANCE’); a decreased severity of side effects (positive
signs for ‘MILD SIDE EFFECTS’ and ‘MODERATE SIDE
EFFECTS’); and improved appearance (positive signs for
‘NORMAL APPEARANCE’, and ‘MODERATE CHANGE
IN APPEARANCE’). No a-priori assumptions were made
concerning their preferred alternative (represented by the
alternative specific constants (ASCs) for ‘surgery’ and ‘imi-
quimod cream’ options, ‘ASCSURGERY‘and ‘ASCCREAM’).
Subgroup analysis was undertaken to test whether dif-
ferent choices may result if respondents had experience
of BCC and treatment. This follows current evidence in
health care, reporting that respondents usually ascribe
more value to the things they have experienced, (i.e. sta-
tus quo bias: see Salkeld et al. [11]). The MLM model
was presented considering all valid respondents (whole
sample) and subgroups of those with experience and
with no experience of BCC and treatment.
Estimated preferences were compared between experi-
ence subgroups. Difference in i) incremental WTP or ii)
in proportion of respondents with preferences for a par-
ticular change in treatment characteristics (described by
their mean and standard deviation) were reported and
tested using independent t test statistics.
Results and discussion
Response rates, patient characteristics, and questionnaire
completion
The DCE questionnaire was completed by 174/183 (95%)
consecutive SINS trial participants. Overall 22% consid-
ered the questionnaire difficult/very difficult to complete
(Table 2). The median age of the respondents was 65 years,
61% were men, 80% had a weekly income less than £300,
and about 32% had previous experience of symptoms and
treatment for BCC. Both subgroups with experience and
with no experience presented socioeconomic characteris-
tics similar to the whole DCE sample (See Table 2).Patient preferences
Specifications of the MLM model, its output for analys-
ing the whole sample and subgroups with and without
previous BCC are presented in Tables 3, 4. Figures 2, 3
display mean utility values and marginal WTP attached
to the alternative treatments and their characteristics. The
proportion of respondents for whom a particular charac-
teristic had a positive effect is illustrated in Figure 4.
In the whole group and subgroups with and without
previous BCC, all treatment choice attributes are statisti-
cally significant at 95% and therefore significant in the
decision to choose. There is also evidence that indivi-
duals valued these characteristics differently. Overall, all
characteristics have the expected directions supporting
theoretical validity of the findings (see above). The posi-
tive signs on the alternative specific constants (ASCs) in-
dicate that, everything else being equal, respondents
preferred alternative treatments to their ‘current situ-
ation’, and, when choosing an alternative to their ‘current
situation’, the ‘imiquimod cream’ was preferred overall to
the ‘surgery’ (as indicated by the higher positive value).
See Tables 3, 4 for further details.Whole sample
Across all treatment characteristics choosing mild instead
of severe side effects was the most valued aspect (as indi-
cated by the largest significant coefficient of ‘MILD SIDE
EFFECTS’ with a mean value of 1.38), whilst an increase
in cost was the least preferred (‘COST’ with a mean value
of −0.0031; see Figure 2).
Figure 3 and Table 3 also show respondents’ marginal
WTP for a unit change in each treatment characteristic.
For example, marginal WTP for choosing mild instead of
severe side effects is £445.16 (standard deviation £541.94).
The proportion of respondents for whom a particular
characteristic had a positive effect is reported in Figure 4,
Table 3. For example, 79% of the sample preferred a
change from severe to mild side effects, while the others
did not value this change so highly.Subgroup with experience of BCC and treatment
For those with previous BCC experience, the movement
from severe change to normal appearance was the most
important marginal change in an attribute (having the
largest significant coefficient with a mean value of 1.31),
and ‘COST’ remained the least preferred characteristic
(see Figure 2, Table 4). The marginal WTP for choosing
normal instead of severe change to appearance is
£392.22 (standard deviation £377.25; Figure 3, Table 4).
Ninety seven percent of the sample preferred normal ap-
pearance where as the others did not value this change
so highly (Figure 4, Table 4).
Table 2 Patient characteristics (whole sample and subgroups relating to experience of BCC symptoms and treatment)
Whole sample
N=174
With no experience
N=118
With experience
N=56
With no vs.
with experience
% (n) % (n) % (n) P value
Gender 0.3
Male 60.9 (106) 63.6 (75) 55.4 (31)
Female 39.1 (68) 36.4 (43) 44.6 (25)
Age 0.1
Median [IQR] 65 [57–72] 63 [55–72] 68 [60–72]
Employment status N.A. 1
Employed 35.6 (62) 39.8 (47) 26.8 (15)
Retired 63.2 (110) 59.3 (70) 71.4 (40)
Unemployed 1.2 (2) 0.9 (1) 1.8 (1)
Weekly income2 0.21
<£299 50.0 (80) 44.9 (53) 48.2 (27)
£300-499 19.5 (34) 20.3 (24) 17.9 (10)
£>=500 19.5 (34) 19.5 (23) 19.6 (11)
(Not recorded to be
excluded from analysis)
14.9 (26) 15.3 (18) 14.3 (8)
Previous experience of BCC symptoms and treatment
Yes 32.2 (56) 0 (0) 100 (56)
No 67.8 (118) 100 (118) 0 (0)
Difficulties in completing the questionnaire N.A. 1
Extremely easy 13.2 (23) 9.3 (11) 21.4 (12)
Easy 28.7 (50) 26.3 (31) 33.9 (19)
Moderate 35.6 (62) 39.8 (47) 26.8 (15)
Difficult 16.1 (28) 16.1 (19) 16.1 (9)
Extremely difficult 6.3 (11) 8.5 (10) 1.8 (1)
1 Cells have expected count less than 5. 2Some respondents presented not recorded data, as the question was not asked (dropped from assessments) or they did
not complete it.
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treatment
With no BCC experience, the movement from severe
to mild side effects was the most important marginal
change in an attribute (having largest significant coeffi-
cient with a mean value of 1.37), and ‘COST’ remained
the least preferred characteristic (see Figure 2, Table 4).
The marginal WTP when choosing mild instead of se-
vere side effects was £455.15 (Figure 3, Table 4). Of
the sample 80% preferred mild instead of severe side
effects, while the others did not value this change so
highly (Figure 1, Table 4).
Comparison between subgroups
Respondents preferred a change from the ‘current situ-
ation’ to alternative treatments and they mostly preferred
moving to the ‘imiquimod cream’, regardless of their ex-
perience of a previous BCC and treatment. The subgroup
with no experience valued more such change compared
with the subgroup with experience (‘ASCCREAM’; £1013
vs. £781). The subgroup with no experience valued bestchoosing mild instead of severe side effects, and
their willingness to pay for this choice was similar to
the other subgroup (‘MILD SIDE EFFECTS’; £455 vs.
£344, p=0.23). In the subgroups with experience the
most valued characteristic was an improvement in
their appearance from severe changes to normal ap-
pearance and they valued it more than the subgroup
with no experience (‘NORMAL APPEARANCE’; £392
vs. £299, p=0.02). More details are presented in Figure 3
and Table 4.
When considering the difference in preference distri-
bution across groups a greater proportion of participants
with experience compared with no experience preferred
the idea of a change from severe to moderate side effects
(‘MODERATE SIDE EFFECTS’; 99% vs. 87%, p<0.01), or
from severe change to normal appearance (‘NORMAL
APPEARANCE’; 97% vs. 85%, p<0.01; see Table 4). Other
random coefficient distributions did not present statistically
significant differences between groups (‘CHANCE’ p=0.13;
‘MILD SIDE EFFECTS’ p=0.45; ‘MODERATE CHANGE
IN APPEARANCE’ p=0.11).
Table 3 Patient preferences for the whole sample (n=174)
Whole sample
Regression1 Incremental
WTP2 (£)
Their preference is for:
Value (SD) Value (SD)
ASC SURGERY Coefficient 1.4200 (0.253) 458.06 - Surgery (compared with current situation)
ASC CREAM Coefficient 2.8700 (0.398) 925.81 - Imiquimod cream (compared
with current situation)
COST Coefficient −0.0031 (0.000) - - Decreased cost
CHANCE Mean 0.1090 (0.018) 35.16 (38.71) increased chance, 82% of respondents
SD 0.1200 (0.022)
MILD SIDE EFFECTS Mean 1.3800 (0.314) 445.16 (541.94) mild side effects (compared
with severe, 79% of respondents)
SD 1.6800 (0.282)
MODERATE SIDE EFFECTS Mean 0.8390 (0.265) 270.65 (199.68) moderate side effects (compared with
severe, 91% of respondents)
SD 0.6190 (0.396)
NORMAL APPEARANCE Mean 1.0200 (0.265) 329.03 (267.74) normal appearance (compared with
severe change, 89% of respondents)
SD 0.8300 (0.333)
MODERATE CHANGE
IN APPEARANCE
Mean 0.5400 (0.345) 174.19 (548.39) moderate change (compared with
severe change, 62% of respondents)
SD 1.7000 (0.274)
Number of respondents 174
Number of observations 2765 (=171 respondents *16 choices +1respondents*14 choices+1 respondent*8 choices+
1 respondent*7 choices)
Log-likelihood −2013.9
Adjusted Rho-square 0.333
LR statistic 2047.47
1The preferred model is a MLM and presents all characteristics (apart from ‘COST’, ‘ASCSURGERY’, ‘ASCCREAM’) as random and independently normally distributed. The
simulation process is based on 500 draws. All coefficients (either fixed or random) and the standard deviations of the random coefficients are statistically
significant at 95%. 2WTP estimates are based on the regression results in column 3 and rounded to 2 decimal places. The standard deviations are in parentheses.
Marginal WTP for a unit change in a treatment characteristic = (mean coefficient of characteristic)/-(coefficient ‘COST’), with SD = (SD of characteristic coefficient)/
-(coefficient ‘COST’).
Note: Alternative specific constants (ASC) for surgery (ASC SURGERY) and for cream (ASC CREAM) show the preferences of these alternatives relative to the current
situation, everything else being equal.
Key: SD = standard deviation, WTP = Willingness to Pay, LR = Likelihood Ratio.
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This Discrete Choice Experiment (DCE) exercise was
embedded within a wider randomised controlled trial.
This provided the main trial with new empirical evi-
dence of strength of patient preferences for alternative
treatments on offer for low risk BCC, the impact of pre-
vious experience of a BCC and treatment on their pre-
ferences, and a measure of the spread or heterogeneity of
preferences in the sample.
To our surprise, respondents preferred the ‘imiquimod
cream’ treatment to their ‘current situation’ or alterna-
tive ‘surgery’, regardless of their experience of a previous
BCC and treatment, though it might be questioned
whether respondents with no experience of a condition
or treatment are in a position to inform decision making
(Gafni [22]).Our study showed that regardless of their experience,
respondents valued all aspects of treatment, but they
were more likely to be worried about their cosmetic out-
comes and side effects they might experience over and
above their chance of clearance and cost. A cream
option with better cosmetic outcomes was more
appealing to them than a surgery intervention with
better clearance outcomes.
Respondents with experience of a previous BCC and
treatment (usually surgical) valued the ‘imiquimod cream’
option less than those without such experience, a finding
supported in the literature of status quo bias, where people
are more likely to adopt a conservative response to health
services innovations (Salkeld et al. [11]; Ryan and Ubach
[12]; Tinelli et al. [23]). In this particular case respondents’
experience for a surgery intervention might have limited
Table 4 Patient preferences according to experience of BCC and treatment
With experience With no experience
Regression1 Incremental WTP (£) Their preference is for: Regression1 Incremental WTP (£) Their preferences is for:
Value (SD) Value (SD) Value (SD) Value (SD)
ASC SURGERY Coefficient 1.6300 (0.457) 488.02 - Surgery (compared
with current situation)
1.3400 (0.310) 445.18 - Surgery (compared with
current situation)
ASC CREAM Coefficient 2.6100 (0.719) 781.44 - Imiquimod cream (compared
with current situation)
3.0500 (0.488) 1013.29 - Imiquimod cream (compared with
current situation)
COST Coefficient −0.0033 (0.001) Decreased cost −0.0030 (0.001) Decreased cost
CHANCE2 Mean 0.0898 (0.033) 26.89 (44.61) Increased chance (compared
with deceased; 73% of
respondents)
0.1210 (0.026) 40.20 (37.54) Increased chance (compared with
decreased; 86% of respondents)
SD 0.1490 (0.058) 0.1130 (0.023)
MILD SIDE EFFECTS Mean 1.1500 (0.553) 344.31 (616.77) Mild side effects
(compared with severe;
71% of respondents)
1.3700 (0.390) 455.15 (541.53) Mild side effects (compared with
severe; 80% of respondents)
SD 2.0600 (0.474) 1.6300 (0.327)
MODERATE SIDE
EFFECTS 2–3
Mean 1.1600 (0.480) 347.31 (−153.89) Moderate side effects
(compared with severe;
99% of respondents)
0.6710 (0.312) 222.92 (−199.67) Moderate side effects (compared
with severe; 87% of respondents)
SD 0.5140 (0.519) 0.6010 (0.423)
NORMAL
APPEARANCE2-3
Mean 1.3100 (0.531) 392.22 (377.25) Normal appearance (compared
with severe change; 97% of
respondents)
0.9000 (0.304) 299.00 (158.80) Normal appearance (compared with
severe change, 85% of respondents)
SD 1.2600 (0.633) 0.4780 (0.498)
MODERATE CHANGE
IN APPEARANCE
Mean 0.9230 (0.564) 276.35 (407.19) Moderate change
(compared with severe;
75% of respondents)
0.4630 (0.433) 153.82 (634.55) Moderate change (compared
with severe; 60% of respondents)
SD 1.3600 (0.539) 1.9100 (0.408)
No. respondents 56 118
No. observations 896 (=56 respondents*16 choices) 1869 (=115 respondents*16 choices+
1 respondent*14 choices+1 respondent*
8 choices+1 respondent*7 choices)
Log-likelihood −649.27 −1350.8
Adj Rho-square 0.327 0.336
LR statistic 670.18 1405.08
Note: Alternative specific constants (ASC) for surgery (ASCSURGERY) and for cream (ASCCREAM) show the preferences of these alternatives relative to the current situation, everything else being equal. WTP estimates are
based on the regression results in column 3 and rounded to 2 decimal places. The standard deviations are in parentheses. 1 The preferred model is a MLM and presents all characteristics (apart from ‘COST’,
‘ASCSURGERY’, ‘ASCCREAM’) as random and independently normally distributed. The simulation process is based on 500 draws. All coefficients (either fixed or random) and the standard deviations of the random
coefficients are statistically significant at 95% 2 Differences in marginal WTP between groups are significant at the 95% level. 3Differences in preference distribution between groups are significant at the 99% level.
Key: SD = standard deviation, WTP = Willingness to Pay, LR = Likelihood Ratio, No. = Number of.
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Figure 2 Modelling patient preferences: Utility values. Note: This Figure reports on average values only, whilst the complete output from the
logistic regression model is presented in Tables 3 (whole sample) and 4 (subgroups with experience and with no experience of BCC symptoms and
treatment). Alternative specific constants (ASC) for surgery (ASC SURGERY) and for cream (ASC CREAM) show the preferences of these alternatives
relative to the current situation, everything else being equal. The cost attribute reported a mean value of −0.0031, and therefore it is less
noticeable than the other attributes. Due to differences in scale factors across data sets, utility values from different subgroups are not directly
comparable. For comparison between subgroups with experience and with no experience of BCC symptoms and treatment please see marginal
WTP (Figure 3) and proportion of respondents (Figure 4). Overall findings from subgroup analyses are also presented in Table 4.
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innovative ‘imiquimod cream’ intervention on offer.
With experience of a previous BCC and surgical inter-
vention (with risk of permanent scar), the movement
from severe change to normal appearance was the most
important marginal change; this subgroup were more
likely to value a treatment with the best cosmetic out-
comes, regardless of other characteristics, compared
with those with no previous BCC.
How people differed
Evidence of significant variation (heterogeneity) of prefer-
ences was found in the chance of clearance, side effects
and appearance characteristics. Preferences for treatmentcharacteristics were not specific to one particular im-
provement in their cosmetic outcomes or chance of clear-
ance, though some changes might be regarded as not
sufficient e.g. only 62% preferring moderate change vs. se-
vere change. The distributions of preference were statisti-
cally different across experience subgroups. Results
confirmed that respondents with experience of a BCC
were more likely to value a treatment with the best cos-
metic outcomes, whilst respondents with no past BCC
might value less highly such improved characteristics.
Study strengths and limitations
A particular strength was using a multiple choice de-
sign with inclusion of a status quo option; forcing a
Figure 3 Modelling patient preferences: Marginal WTP values (£). Note: This Figure reports on mean values only, whilst the complete output
from the logistic regression model, marginal WTP calculations (mean and standard deviation values), and their comparison between subgroups is
presented in Tables 3 (whole sample) and 4 (subgroups with experience and with no experience of BCC symptoms and treatment). For ‘CHANCE’,
‘MODERATE SIDE EFFECTS’ and ‘NORMAL APPEARANCE’ differences in marginal WTP between subgroups (with experience vs. with no experience of
BCC symptoms and treatment) are significant at the 95% level.
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the reality may result in an overestimation of responses
(Boyle et al. [24]).
Other strengths included exploring heterogeneity of
responses, and the mixed logit model (MLM) allowed
statistical investigation of how preferences varied
across groups. Information on variation (heterogeneity)
of preferences is recognised as an important aspect
when integrating patient views into decision making
(de Bekker-Grob et al. [15]). A MLM was applied to the
data as it is commonly used to analyse multiple choice
health care data (de Bekker-Grob et al. [15]), although al-
ternative models, such as the latent class model, could
also be adopted (Hensher et al. [25] Hensher and Greene
[26]). Our modelling study also confirmed the import-
ance of exploring preference variation across groups to
better understand and implement innovative services onoffer. Patient knowledge of the condition and treatment
experience might provide more informed choice.
A limitation is that participants in this study are un-
likely to have experienced topical imiquimod, thus we
could not assess how previous imiquimod experience
influenced their preferences (including the risk of pos-
sible reactions/side effects to the treatment), whereas we
could at least partly with surgical excision as some had
already experienced it for a previous BCC. It would have
been informative to analyse the DCE further, for
example, comparing any changes in patient preferences
later in the study after experiencing surgery or imiqui-
mod cream. Also, patients with both nodular and
superficial BCC were included in the current analysis.
Future studies could aim to collect larger sample sizes
to perform a subgroup analysis according to the type
of BCC affecting the patients. Time constraints did
Figure 4 Modelling patient preferences: the proportion of respondents (%) with positive effect of particular characteristic. Note: The
output from the logistic regression model used to inform these estimates is presented in Tables 3 (whole sample) and 4 (subgroups with
experience and with no experience of BCC symptoms and treatment, and their comparison). For ‘MODERATE SIDE EFFECTS’ and ‘NORMAL
APPEARANCE’ differences in preference distribution between subgroups (with experience vs. with no experience of BCC symptoms and treatment)
are significant at the 95% level.
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choice of the attributes and their levels with patient
interviews and focus groups. Other attribute levels
(e.g. different levels for the cost attributes pending
on the specific treatment compared) could be con-
sidered for future exercises and informed by trial
economic evaluation.
Although our 95% overall response rate was high,
respondents in this DCE survey might not have been rep-
resentative of all BCC patients because they are all partici-
pants in the SINS trial, who by definition are more
equipoise and willing to consider both options of ‘imiqui-
mod cream’ and alternative ‘surgery’ intervention; also it is
not a random sample. Most patients (with or without pre-
vious surgical experience) who had a strong preference for
a status quo approach with surgical excision would prob-
ably not have chosen to participate in the SINS trial, and
therefore their preferences were not captured by this DCE
survey. Of those choosing not to take part in the study
48% (126/265) gave the reason as wanting to have surgery.A further seven dropped out of the study after
randomisation because they did not want surgery.
The DCE can provide very useful information, but the
completion difficulties and time taken in this elderly
population (median age 68, up to a maximum of 92 years)
are not to be underestimated – many found it difficult to
understand the concept of choosing between hypothetical
situations and hence took up to an hour to complete. The
research nurse helped them to understand what they had
to do. The results showed, however, consistency of
answers, suggesting that participants were not just making
random choices. DCE surveys will benefit from providing
participants with help and support from experienced re-
search staff during questionnaire completion if needed.
Although this research refers to a representative group
of mainly elderly patients in the UK with low risk BCC,
our findings of attitudes and preference to treatment
options may not be generalisable to other countries and
ethnic groups. It is also important to emphasise the low
risk nature of this BCC population. The trade-off
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aggressive tumours for example is likely to be different
from those observed in this study population.
Conclusions
Understanding how people with BCC value alternative
interventions using the DCE technique may better
inform the development of health care interventions,
although this particular application proved data collection
to be challenging and time consuming; elderly participants
are likely to need help and support.
Additional file
Additional file 1: “Questionnaire for SINS study”. Contains the
questionnaire used to collect DCE responses from each respondent.
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